Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maria George Elias has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Potent Antineoplastic Activity against Breast Cancer in Vitro and in Vivo of a Chloro-Substituted Polyaromatic Platinum(II) Complex and Its Platinum(IV) Prodrug

    by Omar Hammoud, Maria George Elias, Amjad Slika, Aleen Khoury, Stephanie Mehanna, Joelle Abou Chacra, Selim Nasser, Janice R. Aldrich-Wright, Costantine F. Daher, Robin I. Taleb

    This study investigates the chemotherapeutic potential of PtII5CLSS and PtIV5CLSS against breast cancer in vivo. Cell viability was assessed 72 h post-treatment, revealing potent cytotoxic activity with IC50 values of 0.447 μM for PtII5CLSS and 0.922 μM for PtIV5CLSS. Cellular uptake studies used ICP-MS to confirm active transport of both complexes into cells, showing significant accumulation in the nuclear/cytoskeletal fractions. A 28-day toxicity study in female Sprague-Dawley rats demonstrated that escalating doses up to 15 mg/kg (PtII5CLSS) and 30 mg/kg (PtIV5CLSS) caused no mortality nor adverse effects on liver and kidney function. In a chemically induced breast cancer rat model, both complexes significantly reduced tumor weight by 93–100% at doses of 1 and 5 mg/kg, with no observable nephrotoxicity or hepatotoxicity. Histopathological analysis confirmed the reduction or absence of tumors in the majority of the treated animals with PtIV5CLSS (1 mg/kg bw) being the most effective. Toxicity evaluation in sus scrofa pigs showed that PtIV5CLSS was well tolerated at both 1- and 2.5 mg/kg bw, with no mortality, behavioral changes, or signs of acute toxicity. Overall, both PtII5CLSS and PtIV5CLSS demonstrate strong antineoplastic activity against breast cancer with a favorable safety profile, supporting their potential as alternative platinum-based chemotherapeutic agents.

  • Open Access

    Human Group IIA Secreted Phospholipase A2 and the Prostate Cancer Tumor Microenvironment: Potential Mechanisms

    by Monavvar Andarva, Maria George Elias, Mila Sajinovic, Tara Laurine Roberts, Paul de Souza, Kieran F. Scott

    Human secreted phospholipase A2 group IIA (hGIIA) is a Ca2+-dependent extracellular enzyme that supports host defense and amplifies inflammation through lipid mediator generation and receptor-linked signaling. In prostate cancer (PCa), hGIIA is commonly elevated compared with benign tissue and can persist after androgen deprivation, implicating it in tumor progression. PCa is typically an immunologically “cold” disease sustained by an immunosuppressive tumor microenvironment enriched in regulatory T cells ( Treg), myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), and pro-tumor stromal cells, alongside hypoxia and metabolic rewiring. Because hGIIA is released by innate immune cells and is inducible in macrophages, it is well positioned to strengthen inflammatory lipid networks and promote immune dysfunction within the prostate tumor microenvironment. Here, we review the PCa microenvironment and evaluate evidence linking hGIIA to tumor–stroma crosstalk, angiogenic programming, and therapy resistance, highlighting major knowledge gaps in prostate-focused immune studies.

  • Open Access

    Chemotherapeutic Potential of Fluorouracil‐Platinum (IV) Prodrugs Against Cisplatin‐Resistant Colorectal Cancer Cells

    by Maria George Elias, Aleen Khoury, Shadma Fatima, Timothy J. Mann, Shawan Karan, Meena Mikhael, Paul de Souza, Christopher P. Gordon, Kieran F. Scott, Janice R. Aldrich‐Wright

    Fluorouracil‐platinum(IV) prodrugs represent a novel class of multimechanistic chemotherapeutics with enhanced anticancer potential. The prodrugs Pt IV P‐5FUMeOBut and Pt IV 56‐5FUMeOBut were actualized by derivatising the clinical drug 5‐fluorouracil (5FU) and coordinating it to platinum(IV) complexes, leveraging the established cytotoxicity of their platinum(II) precursors, Pt II PHEN SS and Pt II 56ME SS . The rationale behind this design is to combine the DNA synthesis‐disrupting antimetabolite activity of 5FU with platinum‐based cytotoxicity, aiming to enhance therapeutic efficacy. This study evaluates the in vitro potency of Pt IV P‐5FUMeOBut and Pt IV 56‐5FUMeOBut in colorectal cancer models, assessing their cellular uptake, cytotoxicity, and effects in 3D spheroid cultures. Comparative analyses with cisplatin and 5FU explore their impact on cell survival, reactive oxygen species production, mitochondrial membrane potential, and cell‐cycle progression. Mechanistic insights are further examined through apoptosis and necrosis assays, proteomic profiling, and western blot analysis of key signalling pathways. These findings contribute to the preclinical development of fluorouracil‐platinum(IV) prodrugs as potential candidates for cancer therapy.

  • Open Access

    The Quest for Non-Invasive Diagnosis: A Review of Liquid Biopsy in Glioblastoma

    by Maria George Elias, Harry Hadjiyiannis, Fatemeh Vafaee, Kieran F. Scott, Paul de Souza, Therese M. Becker, Shadma Fatima

    Background: Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumour, associated with poor survival outcomes and significant clinical challenges. Conventional diagnostic methods, including MRI, CT, and histopathological analysis of tissue biopsies, are limited by their inability to reliably distinguish treatment effects from true tumour progression, often resulting in misdiagnosis and delayed intervention. Repeated tissue biopsies are also invasive and unsuitable for longitudinal monitoring. Liquid biopsy, a minimally invasive approach analysing tumour-derived material in biofluids such as blood and cerebrospinal fluid (CSF), offers a promising alternative. This review aims to evaluate current evidence on circulating biomarkers including circulating tumour cells (CTCs), circulating tumour DNA (ctDNA), microRNAs (miRNAs), extracellular vesicles (EVs), and proteins in GBM diagnosis and monitoring, and to assess the potential role of artificial intelligence (AI) in enhancing their clinical application. Methods: A narrative synthesis of the literature was undertaken, focusing on studies that have investigated blood- and CSF-derived biomarkers in GBM patients. Key aspects evaluated included biomarker biology, detection techniques, diagnostic and prognostic value, current technical challenges, and progress towards clinical translation. Studies exploring AI and machine learning (ML) approaches for biomarker integration and analysis were also reviewed. Results: Liquid biopsy enables repeated and minimally invasive sampling of tumour-derived material, reflecting the genetic, epigenetic, proteomic, and metabolomic landscape of GBM. Although promising, its translation into routine clinical practice is hindered by the low abundance of circulating biomarkers and lack of standardised collection and analysis protocols. Evidence suggests that combining multiple biomarkers improves sensitivity and specificity compared with single-marker approaches. Emerging AI and ML tools show significant potential for improving biomarker discovery, integrating multi-omic datasets, and enhancing diagnostic and prognostic accuracy. Conclusions: Liquid biopsy represents a transformative tool for GBM management, with the capacity to overcome limitations of conventional diagnostics and provide real-time insights into tumour biology. By integrating multiple circulating biomarkers and leveraging AI-driven approaches, liquid biopsy could enhance diagnostic precision, enable dynamic disease monitoring, and improve clinical decision-making. However, large-scale validation and standardisation are required before routine clinical adoption can be achieved.


  • Open Access

    The Quest for Non-Invasive Diagnosis: A Review of Liquid Biopsy in Glioblastoma

    by Maria George Elias, Harry Hadjiyiannis, Fatemeh Vafaee, Kieran F Scott, Paul de Souza, Therese M Becker, Shadma Fatima

    Glioblastoma multiforme (GBM) remains the most common and fatal primary brain tumour, with low survival rates due to its heterogeneous nature. Traditional diagnostic methods, such as magnetic resonance imaging (MRI), computed tomography (CT) scans, and invasive tissue biopsies for histopathological analysis, are often insufficient in differentiating treatment-related changes from tumour progression, leading to misdiagnosis and delays. Repeated biopsies are impractical for ongoing monitoring due to their invasive nature. A promising alternative is liquid biopsy, a minimally invasive procedure that analyses biofluids like blood and cerebrospinal fluid (CSF) for tumour-related biomarkers. Tumours release a variety of components into the bloodstream, including circulating tumour cells (CTCs), circulating tumour DNA (ctDNA), microRNAs (miRNAs), extracellular vesicles (EVs), and proteins, which can cross the blood-brain barrier and provide a non-invasive means of assessing genetic, epigenetic, proteomic, and metabolomic markers associated with GBM. Liquid biopsy can be performed multiple times throughout the disease course, offering a rapid way to gather critical and changing tumour information. However, challenges remain in the clinical implementation of liquid biopsies for GBM diagnosis, including low levels of circulating biomarkers and the lack of standardised assays for biofluid collection and analysis. Combining multiple biomarkers from various bio-elements, such as CTCs, ctDNA, miRNAs, and EVs, could enhance sensitivity and specificity, addressing some of these limitations. The integration of artificial intelligence (AI) for analysing liquid biopsy biomarkers holds great promise in overcoming these challenges. AI can enhance biomarker identification, improve diagnostic accuracy, and expand the clinical utility of liquid biopsy in GBM management. Further research, and large-scale clinical validation are needed to optimise these approaches. This review explores the potential of GBM biomarkers found in blood and CSF samples, focusing on their applications in diagnosis, prediction, and prognosis, and highlights recent advancements, challenges, and future perspectives, including the integration of AI to improve outcomes in GBM management. Liquid biopsies bridge the gap between invasive methods and emerging technologies, offering transformative potential for GBM diagnosis and treatment.


  • Open Access

    Chemotherapeutic Potential of Chlorambucil-Platinum(IV) Prodrugs against Cisplatin-Resistant Colorectal Cancer Cells

    by Maria George Elias, Angelico D. Aputen, Shadma Fatima, Timothy J. Mann, Shawan Karan, Meena Mikhael, Paul de Souza, Christopher P. Gordon, Kieran F. Scott, Janice R. Aldrich-Wright

    Chlorambucil-platinum(IV) prodrugs exhibit multi-mechanistic chemotherapeutic activity with promising anticancer potential. The platinum(II) precursors of the prodrugs have been previously found to induce changes in the microtubule cytoskeleton, specifically actin and tubulin of HT29 colon cells, while chlorambucil alkylates the DNA. These prodrugs demonstrate significant anticancer activity in 2D cell and 3D spheroid viability assays. A notable production of reactive oxygen species has been observed in HT29 cells 72 h post treatment with prodrugs of this type, while the mitochondrial membrane potential was substantially reduced. The cellular uptake of the chlorambucil-platinum(IV) prodrugs, assessed by ICP-MS, confirmed that active transport was the primary uptake mechanism, with platinum localisation identified primarily in the cytoskeletal fraction. Apoptosis and necrosis were observed at 72 h of treatment as demonstrated by Annexin V-FITC/PI assay using flow cytometry. Immunofluorescence measured via confocal microscopy showed significant changes in actin and tubulin intensity and in architecture. Western blot analysis of intrinsic and extrinsic pathway apoptotic markers, microtubule cytoskeleton markers, cell proliferation markers, as well as autophagy markers were studied post 72 h of treatment. The proteomic profile was also studied with a total of 1859 HT29 proteins quantified by mass spectroscopy, with several dysregulated proteins. Network analysis revealed dysregulation in transcription, MAPK markers, microtubule-associated proteins and mitochondrial transport dysfunction. This study confirms that chlorambucil-platinum(IV) prodrugs are candidates with promising anticancer potential that act as multi-mechanistic chemotherapeutics.


  • Open Access

    Anticancer Effect of PtIIPHENSS, PtII5MESS, PtII56MESS and Their Platinum(IV)-Dihydroxy Derivatives against Triple-Negative Breast Cancer and Cisplatin-Resistant Colorectal Cancer

    by Maria George Elias, Shadma Fatima, Timothy J. Mann, Shawan Karan, Meena Mikhael, Paul de Souza, Christopher P. Gordon, Kieran F. Scott, Janice R. Aldrich-Wright

    Development of resistance to cisplatin, oxaliplatin and carboplatin remains a challenge for their use as chemotherapies, particularly in breast and colorectal cancer. Here, we compare the anticancer effect of novel complexes [Pt(1,10-phenanthroline)(1S,2S-diaminocyclohexane)](NO3)2 (PtIIPHENSS), [Pt(5-methyl-1,10-phenanthroline)(1S,2S-diaminocyclohexane)](NO3)2 (PtII5MESS) and [Pt(5,6-dimethyl-1,10-phenanthroline)(1S,2S-diaminocyclohexane)](NO3)2 (PtII56MESS) and their platinum(IV)-dihydroxy derivatives with cisplatin. Complexes are greater than 11-fold more potent than cisplatin in both 2D and 3D cell line cultures with increased selectivity for cancer cells over genetically stable cells. ICP-MS studies showed cellular uptake occurred through an active transport mechanism with considerably altered platinum concentrations found in the cytoskeleton across all complexes after 24 h. Significant reactive oxygen species generation was observed, with reduced mitochondrial membrane potential at 72 h of treatment. Late apoptosis/necrosis was shown by Annexin V-FITC/PI flow cytometry assay, accompanied by increased sub-G0/G1 cells compared with untreated cells. An increase in S and G2+M cells was seen with all complexes. Treatment resulted in significant changes in actin and tubulin staining. Intrinsic and extrinsic apoptosis markers, MAPK/ERK and PI3K/AKT activation markers, together with autophagy markers showed significant activation of these pathways by Western blot. The proteomic profile investigated post-72 h of treatment identified 1597 MDA−MB−231 and 1859 HT29 proteins quantified by mass spectroscopy, with several differentially expressed proteins relative to no treatment. GO enrichment analysis revealed a statistically significant enrichment of RNA/DNA-associated proteins in both the cell lines and specific additional processes for individual drugs. This study shows that these novel agents function as multi-mechanistic chemotherapeutics, offering promising anticancer potential, and thereby supporting further research into their application as cancer therapeutics.


  • Open Access

    Platinum(IV) Prodrugs Incorporating an Indole-Based Derivative, 5-Benzyloxyindole-3-Acetic Acid in the Axial Position Exhibit Prominent Anticancer Activity

    by Angelico D. Aputen, Maria George Elias, Jayne Gilbert, Jennette A. Sakoff, Christopher P. Gordon, Kieran F. Scott, Janice R. Aldrich-Wright

    Kinetically inert platinum(IV) complexes are a chemical strategy to overcome the impediments of standard platinum(II) antineoplastic drugs like cisplatin, oxaliplatin and carboplatin. In this study, we reported the syntheses and structural characterisation of three platinum(IV) complexes that incorporate 5-benzyloxyindole-3-acetic acid, a bioactive ligand that integrates an indole pharmacophore. The purity and chemical structures of the resultant complexes, P-5B3A, 5-5B3A and 56-5B3A were confirmed via spectroscopic means. The complexes were evaluated for anticancer activity against multiple human cell lines. All complexes proved to be considerably more active than cisplatin, oxaliplatin and carboplatin in most cell lines tested. Remarkably, 56-5B3A demonstrated the greatest anticancer activity, displaying GI50 values between 1.2 and 150 nM. Enhanced production of reactive oxygen species paired with the decline in mitochondrial activity as well as inhibition of histone deacetylase were also demonstrated by the complexes in HT29 colon cells.


  • Enhanced potency of a chloro-substituted polyaromatic platinum(II) complex and its platinum(IV) prodrug against lung cancer

    by Joy Baz, Aleen Khoury, Maria George Elias, Najwa Mansour, Stephanie Mehanna, Omar Hammoud, Christopher P. Gordon, Robin I. Taleb, Janice R. Aldrich-Wright, Costantine F. Daher


  • Open Access

    Versatile Platinum(IV) Prodrugs of Naproxen and Acemetacin as Chemo-Anti-Inflammatory Agents

    by Angelico D. Aputen, Maria George Elias, Jayne Gilbert, Jennette A. Sakoff, Christopher P. Gordon, Kieran F. Scott, Janice R. Aldrich-Wright

    Developing new and versatile platinum(IV) complexes that incorporate bioactive moieties is a rapidly evolving research strategy for cancer drug discovery. In this study, six platinum(IV) complexes (1–6) that are mono-substituted in the axial position with a non-steroidal anti-inflammatory molecule, naproxen or acemetacin, were synthesised. A combination of spectroscopic and spectrometric techniques confirmed the composition and homogeneity of 1–6. The antitumour potential of the resultant complexes was assessed on multiple cell lines and proved to be significantly improved compared with cisplatin, oxaliplatin and carboplatin. The platinum(IV) derivatives conjugated with acemetacin (5 and 6) were determined to be the most biologically potent, demonstrating GI50 values ranging between 0.22 and 250 nM. Remarkably, in the Du145 prostate cell line, 6 elicited a GI50 value of 0.22 nM, which is 5450-fold more potent than cisplatin. A progressive decrease in reactive oxygen species and mitochondrial activity was observed for 1–6 in the HT29 colon cell line, up to 72 h. The inhibition of the cyclooxygenase-2 enzyme was also demonstrated by the complexes, confirming that these platinum(IV) complexes may reduce COX-2-dependent inflammation and cancer cell resistance to chemotherapy.